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Pancreatic cancer is an extremely aggressive neoplasm whose ne incidence equals its death rate. Despite intensive analysis, the an genetic changes that mediate pancreatic cancer development and effective therapies for diminishing the morbidity associated with th. this disease remain unresolved. Through subtraction hybridization, an we have identified a gene associated with induction of irreversible be growth arrest, cancer reversion, and terminal differentiation in a human melanoma cells, melanoma differentiation associated oli gene-7 (mda-7). Ectopic expression of mda-7 when using a recom-pa binant adenovirus, Ad.mda-7, results in growth suppression and pa apoptosis in a broad spectrum of human cancers with diverse ge genetic defects, without exerting deleterious effects in normal ap human epithelial or fibroblast cells. Despite the apparently ubiqef: uitous antitumor effects of mda-7, pancreatic carcinoma cells are re( remarkably refractory to Ad.mda-7 induced growth suppression an and apoptosis. In contrast, the combination of Ad.mda-7 with pa antisense phosphorothioate oligonucleotides, which target the viv K-ras oncogene (a gene that is mutated in 85 to 95% of pancreatic co carcinomas), induces a dramatic suppression in growth and a di' decrease in cell viability by induction of apoptosis. In mutant K-ras pr pancreatic carcinoma cells, programmed cell death correlates with im expression and an increase, respectively, in MDA-7 and BAX profu teins and increases in the ratio of BAXto BCL-2 proteins. Moreover, mi transfection of mutant K-ras pancreatic carcinoma cells with an an antisense K-ras expression vector and infection with Ad.mda-7 of inhibits colony formation in vitro and tumorigenesis in vivo in nude on mice. These intriguing observations demonstrate that a combina-cie torial approach, consisting of a cancer-specific apoptosis-inducing gene and an oncogene inactivation strategy, may provide the fib foundation for developing an effective therapy for pancreatic mt cancer.
of en Pancreatic cancer is the fourth leading cause of cancer deaths; to! it is estimated that 29,200 cases will be diagnosed in the US ch in 2001, and 28,900 of these patients will die (1). Moreover, no long-term survival for patients with organ-confined disease is dii only 20%, and in the majority of cases, in which the disease when va diagnosed has already spread past the pancreas, survival is only dii 4% (2-6). These findings underscore the need for developing of improved therapies for this aggressive cancer. Although they are no the subjects of intensive study, the defining molecular determinants of pancreatic cancer and effective therapies for this disease remain elusive (2, [6] [7] [8] parent when using AS PS ODN that did not correspond ecisely to the mutation in K-ras codon 12 of the particular ncreatic carcinoma analyzed. This observation supports nu-,rous previous studies indicating that AS PS ODN can induce th specific and apparently nonspecific effects in target cells )-32). In the present study, AS K-ras PS ODN were designed interact with the AUG start codon of the K-ras gene. eatment of both mut and wt K-ras expressing pancreatic rcinoma cells with AS K-ras PS ODN, but not MM or SC PS )N, reduced K-ras p21 protein levels in both mut and wt K-ras ls by > 80% within 24 h (Fig. 3) . This effect was observed with d without Ad.vec or Ad.mda-7 infection, which did not contently cause a further alteration in K-ras levels (Fig. 3) .
oreover, the growth inhibitory effect of the AS K-ras PS ODN s greater in the three mut K-ras pancreatic carcinoma cells in in the wt K-ras BxPC-3 cell line (Fig. 1). As observed in the idy by Kita et al. (11), growth inhibition induced by AS K-ras ODN, either point or start codon specific (current study),
:eeded that observed when using SC or MM PS ODN. In dition, no synergistic growth inhibitory effects or decreases in 1 survival were apparent in Ad.mda-7 infected pancreatic rcinoma cells that were subsequently treated with SC or MM ODN. These results confirm a profound synergistic growth libitory effect specifically in mut K-ras pancreatic carcinoma ls after infection with Ad.mda-7 and treatment with AS K-ras ODN. 
Plasma membrane-associated small molecular weight GTPiding proteins are frequently used by cells in the process of nal transduction from the inner leaflet of the plasma memme to the cytosol. The prototypical small molecular weight nily of GTP-binding proteins is the ras gene family (33). K-ras a member of the ras gene family, which consists of three imbers, K-ras, H-ras, and N-ras (34). When activated, the RAS )teins contain a bound GTP molecule, whereas the inactive rm contains GDP (35). The process of ras activation involves

